Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.44 |
| ▸ | WNT1 | P04628 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29861041 | 1.00 | MEN1 (0.51) | MEN1KMT2ATMPRSS4USP30DEGS1 | |
| SCHEMBL24931559 | 0.86 | KMT2A (0.47) | MEN1KMT2ADEGS1HCRTR2HCRTR1 | |
| SCHEMBL18838986 | 0.82 | USP30 (0.54) | MEN1KMT2ATMPRSS4USP30DEGS1 | |
| SCHEMBL24931494 | 0.81 | GSK3B (0.46) | USP30HCRTR2HCRTR1WNT1GSK3B | |
| SCHEMBL1430551 | 0.80 | KMT2A (0.57) | MEN1KMT2ATMPRSS4USP30DEGS1 | |
| SCHEMBL24932374 | 0.79 | BRAF (0.40) | MEN1KMT2AHCRTR2HCRTR1WNT1 | |
| SCHEMBL2585205 | 0.78 | MAPT (0.50) | MEN1KMT2A | |
| SCHEMBL24932388 | 0.78 | RAB9A (0.64) | — | |
| SCHEMBL24932386 | 0.78 | DEGS1 (0.53) | DEGS1 | |
| SCHEMBL3715011 | 0.78 | MEN1 (0.58) | MEN1KMT2ATMPRSS4USP30DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027929-A1 | MrgprX2 Antagonists and Uses Thereof | DERMIRA, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027929-A1 | MrgprX2 Antagonists and Uses Thereof | MRGPRX2, MRGPRX1, MRGPRX4 | MEN1 2737/4885KMT2A 3705/4885TMPRSS4 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.